Tim van Hauwermeiren
Gründer bei ARGENX SE
Vermögen: 12 Mio $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Michel Detheux | M | 57 |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 13 Jahre |
| David Hallal | M | 56 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 6 Jahre |
| Ann Rhoads | F | 58 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 4 Jahre |
| Anthony Adam Rosenberg | M | 71 | 7 Jahre | |
| Steve Krognes | M | 55 | 1 Jahre | |
| Ana Cespedes | M | 51 | 2 Jahre | |
| Kimberly McCutcheon Jablonski | F | - | - | |
| Aaron Davis | M | 45 | 4 Jahre | |
| Tony Ho | M | 58 | 3 Jahre | |
| Robert Iannone | M | 57 | 3 Jahre | |
| Beth Delgiacco | F | - | 6 Jahre | |
| Els Beirnaert | M | - |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | - |
| Camilla Sylvest | F | 52 | 2 Jahre | |
| Sandra Ramos-Alves | F | - | - | |
| James Daly | M | 62 | 6 Jahre | |
| Pamela Klein | M | 63 | 8 Jahre | |
| Joseph deBethizy | M | 74 | 9 Jahre | |
| Prabhavathi Fernandes | M | 74 |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | - |
| Joe Bolen | M | 70 |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | - |
| Matthew Call | M | 51 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 5 Jahre |
| John Paul de Koning | M | 55 |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | 9 Jahre |
| David Lee | M | 42 | 1 Jahre | |
| Peter K. M. Verhaeghe | M | 66 | 16 Jahre | |
| Priyanka Belawat | M | 45 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 6 Jahre |
| Adi Osovsky | F | - | 3 Jahre | |
| Karen Massey | F | 45 | 1 Jahre | |
| Vincenzo Bronte | M | - |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
| Hemamalini Moorthy | F | 54 | 2 Jahre | |
| Luc Truyen | M | 59 | 2 Jahre | |
| Filip Borgions | M | - | 9 Jahre | |
| Sophia Park | F | - | - | |
| Peter Ulrichts | M | 44 | 1 Jahre | |
| Karl Gubitz | M | 54 | 3 Jahre | |
| Pierre Coulie | M | - |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
| Yvonne McGrath | M | 50 | 4 Jahre | |
| Philippe Brantegem | M | - | 4 Jahre | |
| Matthew Gall | M | 47 | 4 Jahre | |
| Marc Schorpion | M | 66 | 6 Jahre | |
| Arjen Lemmen | M | 39 | 8 Jahre | |
| Benjamin Hickey | M | 50 | - | |
| Stefano Crosignani | M | - |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
| Jill DeSimone | F | 68 | - | |
| Griet Vanpoucke | M | - |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | 6 Jahre |
| Konstantina Katcheves | F | - | - | |
| Debasish Francois Roychowdhury | M | 63 |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | - |
| Frank Kalkbrenner | M | - |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | - |
| Jonathan Charles Alexander Skipper | M | 59 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
| Al Gray | M | - |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
| Christiana Goh Bardon | M | 53 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 6 Jahre |
| Bart De Taeye | M | - |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Kenneth Song | M | 49 | 4 Jahre | |
| Eric Castaldi | M | 59 | 7 Jahre | |
| Mary Tagliaferri | M | 58 | 3 Jahre | |
| Matt Roden | M | 53 | 3 Jahre | |
| David Lacey | M | 71 | 7 Jahre | |
| Derek DiRocco | M | 43 | 3 Jahre | |
| Aaron Kantoff | M | 29 | 4 Jahre | |
| Werner Lanthaler | M | 56 | 9 Jahre | |
| Aaron Royston | M | 40 | 3 Jahre | |
| Yi Larson | F | 44 | 3 Jahre | |
| Torsten Dreier | M | - | - | |
| Hans J. W. de Haard | M | 64 | - | |
| Maha Katabi | M | 50 | 2 Jahre | |
| Arvind Kush | M | 41 | 3 Jahre | |
| Detlev Biniszkiewicz | M | 56 | 5 Jahre | |
| Ryan Baker | M | - | - | |
| Kelsey Kirk | M | - | - | |
| Wim Parys | M | 64 | 3 Jahre | |
| Jan Van den Bossche | M | - |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | 4 Jahre |
| Jeffrey Woodley | M | - | - | |
| Joanne Lager | M | 52 | 4 Jahre | |
| R. Woods | M | 56 | 5 Jahre | |
| Debbie Allen | M | 64 | - | |
| Alex Rosen | M | 35 | 2 Jahre | |
| Dirk Beeusaert | M | 59 | 5 Jahre | |
| Nicolas Leupin | M | 50 | 3 Jahre | |
| Christy Oliger | F | 54 | 1 Jahre | |
| Ansbert Gadicke | M | 66 | 2 Jahre | |
| Eric Bischoff | M | - | - | |
| Yvonne Greenstreet | M | 61 | 1 Jahre | |
| Richard Heyman | M | 66 | 2 Jahre | |
| Alain Thibault | M | - | - | |
| Angie You | M | 51 | 2 Jahre | |
| Philippe M. R. Guinot | M | - |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
| Harrold van Barlingen | M | 58 | 7 Jahre | |
| Johan Cardoen | M | 65 | 3 Jahre | |
| Bruno Montanari | M | 49 | 7 Jahre | |
| Michael Bart Sheffery | M | 73 | - | |
| Rozalyn Littler | F | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 39 | 43,82% |
| Niederlande | 35 | 39,33% |
| Belgien | 21 | 23,60% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Tim van Hauwermeiren
- Persönliches Netzwerk
